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Introduction
The application of new discoveries and advances in sci-
ence towards commercial use and for public purposes 
depends  mainly  upon  actions  by  entrepreneurs  who 
create  new  technology-based  firms.  However,  in  some 
industries,  such  as  healthcare  and  biotechnology,  the 
high  cost  of  commercialization  makes  it  unlikely  that 
any new, small firm can succeed on its own. To over-
come this challenge, many smaller firms enter into stra-
tegic partnerships with larger firms.
Although the literature on strategic partnerships is well 
developed, the majority of studies focus on large, estab-
lished firms. There is absence of studies that look at stra-
tegic  partnerships  –  and  specifically  the  role  of  open 
innovation – in the development of small and innovat-
ive biotechnology firms. This article addresses this gap 
in the literature with a focus on new firms in the bio-
technology cluster in Belgium, where there is a growing 
trend towards technological and market-driven relation-
ships between large and small biotechnology firms. 
For  this  research,  a  number  of  stock-exchange-listed
biotechnology  firms  in  Belgium  are  screened  and
monitored. Most of these new biotechnology firms are 
unlikely to become fully integrated pharmaceutical com-
panies,  because  they  are  heavily  dependent  on  their 
large strategic partners, especially for: marketing outlets, 
resource  manufacturing  when  they  reach  the  commer-
cialization  stage,  continuing  product  development  ef-
forts, licensing agreements, and milestone payments. 
While  aiming  for  sustainable  growth,  most  of  the  new
biotechnology  firms  in  Belgium  have  not  yet  reached 
this level of maturity and are acutely aware of the pos-
sibility  of  takeover.  The  objective  of  this  article  is  to
develop an understanding of how strategic partnerships 
influence the development of these new and innovative 
biotechnology firms and the role that open innovation 
might play in the success of these relationships. 
This  article  is  structured  as  follows.  The  first  section 
provides an overview of biotechnology business models 
to  show  how  strategic  partnerships  and  open  innova-
tion  are  commonly  leveraged  in  this  industry.  The 
second  section  describes  the  research  methodology  of 
this study. The third section presents the results of this 
study  of  the  biotechnology  sector  in  Belgium.  In  the
final section, conclusions are provided.
Strategic partnerships in the biotechnology industry allow new technology-based firms to 
gain a foothold in this high-cost, high-risk industry. In this article, we examine the impact 
of strategic partnerships and open innovation on the success of new biotechnology firms 
in Belgium by developing multiple case studies of firms in regional biotechnology clusters. 
We find that, despite their small size and relative immaturity, new biotechnology firms are 
able to adopt innovative business models by providing R&D and services to larger firms 
and openly cooperating with them through open innovation. 
Successful innovation is not a single breakthrough. 
It  is  not  a  sprint.  It  is  not  an  event  for  the  solo 
runner. Successful innovation is a team sport, it’s a 
relay race.
Quyen Nguyen
Professor of Surgery
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Biotechnology Business Models and Open
Innovation
To  varying  degrees,  new  biotechnology  firms  depend 
on strategic (technology) partnerships with other organ-
izations or large firms. In most of the partnerships, the 
initial research and innovation developed by the smal-
ler  firms  is  transferred  to  their  larger  counterparts.
According  to  Contracter  and  Lorange  (2002; 
tinyurl.com/colwgoe),  “the  term  “alliances”  covers  several 
governance modalities ranging from relational contract-
ing to licensing, to logistical supply-chain relationships, 
to  equity  joint  ventures  or  to  the  complete  merger  of 
two or more organizations”.
According to Porter (1985; tinyurl.com/bom3jck), “the busi-
ness model outlines how a company generates reven-
ues  with  reference  to  the  structure  of  its  value  chain 
and its interaction with the industry value system”. In 
the  biotechnology  industry,  the  business  model  for  a 
new,  small  company  is  necessarily  dependent  on  col-
laboration  with  other  organizations.  As  Fisken  and 
Rutherford (2002; tinyurl.com/c2xoaxv) explain: “for a bio-
technology company, the business model serves to se-
cure value from the company’s proprietary technology 
and know-how and is currently often heavily reliant on 
large (bio)pharmaceutical or established biotechnology 
company customers, collaborators and partners”. 
Biotechnology companies have traditionally used a vari-
ety of business models to enter the life sciences, phar-
maceutical,  or  healthcare  markets.  Fisken  and 
Rutherford (2002;  tinyurl.com/c2xoaxv) and Pareras (2008; 
tinyurl.com/cch3s52)  distinguish  between  three  key  busi-
ness models based on the value chain structure of the 
biotechnology industry: 
1.  Product-based:  this  vertical  business  model  has  its 
origins in the "fully integrated pharmaceutical com-
pany", where medicines are developed by the com-
pany  from  the  point  of  discovery  up  to  the  end  of 
clinical trials or up to approval. According to Fisken 
and Rutherford (2002; tinyurl.com/c2xoaxv) this business 
model  “aims  to  generate  value  in  progressing 
products  along  the  drug  development  process  and 
either licensing them out to pharmaceutical and top 
tier biotechnology companies or taking them straight 
through to commercialization.” 
2. Platform-based: with this business model, compan-
ies develop a set of tools or integrated technologies 
and license them out. Revenue can be generated rel-
atively  quickly  through  contract  research  and  ser-
vices. Thus, this business model reduce risk and the 
need  for  venture  capital.  Parares  (2008; 
tinyurl.com/cch3s52) calls companies following this mod-
el  “royalty  income  pharmaceutical  companies”. 
These small companies research and develop a new 
drug, which they eventually license to a large pharma-
ceutical company in exchange for a royalty on sales. 
3. Hybrid: this is the dominant business model in the 
biotechnology industry. It is a hybrid of the product-
based  and  platform-based  business  models  and  fo-
cuses on generating a pipeline of products. Investors 
benefit from reduced risks and the possibility of near-
term  revenue  generation.  In  the  hybrid  business 
model, technology platforms are combined with ser-
vices and the creation of products. 
The choice of business model may depend on the type 
of innovation; indeed, Pisano (2006;  tinyurl.com/cmx23cs) 
distinguishes between “types of pharmaceutical innova-
tions which call for vertical integration and which call 
for alliance-building and R&D outsourcing”. However, 
for new, small technology companies the high risk and 
high  cost  of  developing  and  commercializing  a  new 
product on their own make the platform-based and hy-
brid business models attractive.
O’Doherty  (1990;  tinyurl.com/cxekka3)  argues  that  “stra-
tegic partnerships and alliances perhaps represent the 
greatest need but also the greatest challenge for small 
firms and small countries”. The challenges include both 
determining the strategic direction of the firm but also 
finding  "suitable  and  willing"  partners  to  collaborate 
with.  In  the  biotechnology  industry,  open  innovation 
might have a role play in meeting these challenges and 
in the success of the strategic partnerships, both from 
the  perspective  of  new,  small  companies  and  estab-
lished, large companies. As, Nigel Sheail, Head of Glob-
al  Business  Development  &  Licensing  at  Bayer 
HealthCare  (2012;  tinyurl.com/ctqbcap)  says:  "Partnering 
and even open innovation is becoming increasingly im-
portant  for  our  industry  in  a  world  where  health  sys-
tems  are  undergoing  profound  transformations." 
According to the Holst Centre (2013; tinyurl.com/cnskktb), 
an independent open-innovation R&D centre, “due to 
the increased complexity of physics, life-sciences, ma-
terials,  electronics,  software,  etc.,  the  cost  of  R&D  is 
growing  faster  than  company  revenues.  The  goal  of 
partnering is to share ideas and efforts, cost and risk of 
R&D and to reduce the time to market of new product 
generations”.Technology Innovation Management Review April 2013
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In most traditional partnerships in the biotechnology in-
dustry,  smaller  firms  perform  research  and  develop-
ment  for  the  larger  firms  or  transfer  innovations  to 
them.  However,  open  innovation  is  changing  the  way 
these firms interact. In the early stages of R&D, open in-
novation  offers  "a  neutral  platform  for  companies  to 
jointly investigate new and emerging technologies and 
applications,  while  sharing  risks  and  costs"  (Holst 
Centre, 2013; tinyurl.com/cnskktb). 
The  open-innovation  approach  is  providing  new  ways 
for firms of all sizes to collaborate, and it is creating op-
portunities  for  smaller  companies.  For  example,  John-
son  &  Johnson’s  pharmaceutical  division,  Janssen 
(which  was  originally  founded  in  Belgium),  opened  a 
“Concept  Lab  and  Open  Collaboration  Space”  in  San 
Diego  (tinyurl.com/bscccjh).  This  shared  laboratory  –  and 
its open-plan office space – provides life-science entre-
preneurs with an affordable environment for early-stage 
research and encourages interaction between startups. 
According  to  Weverbergh  (2013;  tinyurl.com/cqwgauh), 
“cross pollination between the corporate and the startup 
world – whether through corporate accelerators, ventur-
ing or open innovation like Janssen Labs – is fast becom-
ing the trend that defines 2013”.
Research Methodology
To investigate the impact of strategic partnering – and 
specifically the role of open innovation – on the growth 
and survival of new biotechnology firms, we employed a 
case study research design (Yin, 1984; tinyurl.com/clf7wbd). 
Our focus is new technology companies operating with-
in the biotechnology clusters in Belgium. Through inter-
views  and  available  secondary  data,  we  screened  a 
sample  of  stock-exchange  listed  biotechnology  firms, 
which  are  representative  of  the  Belgian  biotechnology 
industry. These firms were selected based on several cri-
teria  so  that  the  sample  would  include  representation 
from each of the three business models described above 
(i.e., product-based, platform-based, and hybrid). 
We expect to find that:
1. New biotechnology firms located in Belgium will have 
to  work  together  with  international  (bio)pharma-
ceutical firms to create substantial added value.
2. The success of future new biotechnology firms in Bel-
gium  will  depend  on  setting  up  strategic  partnering 
alliances.
3. Most of the new biotechnology firms in Belgium are 
unlikely  to  become  fully  integrated  pharmaceutical 
companies (i.e., they are unlikely to adopt a product-
based business model).
Case Study Results: Biotechnology in Belgium
The  life  sciences  and  biotechnology  have  become  im-
portant sources of new economic development in Bel-
gium,  and  many  new  biotechnology  firms  in  Belgium 
are  university  spin-offs.  Due  to  strong  collaboration 
between research institutes, universities, venture capital-
ists/high-risk finance providers, and existing large com-
panies, strong biotechnology clusters have developed in 
the regions of Flanders (Ghent and Leuven) and Wallo-
nia (Liège and Louvain-La-Neuve). 
The Belgian biotechnology industry is now firmly posi-
tioned as the key player in Europe, with a market capit-
alization  of  about  30%  in  the  eurozone.  Belgium  now 
accounts  for  more  than  150  new  biotech  firms,  which 
represent 7% of European biotechnology firms and 10% 
of R&D expenditures (OECD, 2011; tinyurl.com/bqynwvj). 
Biotechnology  clustering  in  Belgium  is  the  result  of  a 
"regional  innovation  systems"  point  of  view  (Segers, 
1996;  tinyurl.com/cmt8tgr).  The  region-specific  technology 
policy  in  Belgium  (Segers,  1992;  tinyurl.com/cx4uzno)  has 
been organized around two focal points: i) the existence 
of  state-of-the-art  research  potential  in  the  country's 
universities  and  ii)  emerging  technology  centres, 
charged  with  supporting  new  technology-based  firms 
(Segers, 1993; tinyurl.com/bl58bym). 
Over the years, a wide range of incentives have been cre-
ated  for  assisting  new  technology-based  firms.  The 
main categories are:
• financial and fiscal incentives (e.g., the Belgian patent 
income deduction regime)
• employment incentives
• access to seed, venture, and growth capital
• government-supported laboratories and industry-
specific collective research centres
• technology clusters and infrastructural incentives
• establishment of incubators in the proximity of univer-
sities for stimulating and assisting university spin-offsTechnology Innovation Management Review April 2013
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The critical success factors are:
• access to key scientific personnel and mobility of re-
searchers 
• access to seed and venture capital 
• the number of initial public offerings (IPOs)
• operating losses in the early stages of development
• regulatory approval from the Food and Drug Adminis-
tration  (FDA;  fda.gov)  in  the  United  States  and  from 
the European Medicines Agency (EMA; ema.europa
.eu/ema/) in the European Union
• patents and intellectual property rights
• dependence on the strategic large partner(s)
•  expected  revenues  derived  from  the  strategic  large 
partner(s) (e.g., milestone payments)
•  manufacturing,  clinical  trial  and  regulatory  compli-
ance capabilities
Strategic partnerships
Within  Belgium's  strong  regional  clusters,  we  found  a 
large  number  of  strategic  technology  partnerships 
between large, international, and established chemical 
or  (bio)pharmaceutical  firms  and  new  biotechnology 
firms.  Table  1  lists  10  biotechnology  firms  from  this 
study,  along  with  details  of  their  strategic  partnership 
alliances.  While  aiming  for  sustainable  growth,  most 
new  biotechnology  firms  in  Belgium  have  not  yet 
reached an independent stage of maturity and are pre-
dominantly  driven  by  the  takeover  alternative,  as  was 
the case in recent years for Movetis (Shire) and Devgen 
(Syngenta).  Up  to  this  point,  only  ThromboGenics, 
Galapagos, and UCB have succeeded in becoming ma-
ture,  self-sustaining  biotechnology  firms.  Box  1 
provides further detail on the current “star” in the Bel-
gian biotechnology industry: ThromboGenics.
We observed strong collaboration between research in-
stitutions, universities, venture capitalists, high-risk fin-
ance  providers,  existing  large  companies,  and  new 
biotechnology firms. The basic innovative activity occurs 
mainly in university-based new biotechnology firms (i.e., 
new,  small  firms  that  are  spin-offs  from  university  re-
search centres performing state-of-the-art research). 
On the other hand, large and international chemical or 
(bio)pharmaceutical  firms  participate  in  or  establish 
joint  ventures  with  university  research  centres  and 
small,  university-based  new  biotechnology  firms.  Of 
the new biotechnology firms in Belgium that were in-
cluded in this study, most are unlikely to become fully 
integrated  pharmaceutical  companies,  because  they 
are heavily dependent on their strategic large partners, 
especially for marketing outlets, for manufacturing re-
sources when they reach the commercialization stage, 
and for continuing product development efforts. They 
have to rely heavily on licensing agreements and mile-
stone payments. 
Conclusions 
Our case-based analysis of the biotechnology industry 
in  Belgium  shows  that  strategic  technology  partner-
ships  between  new  biotechnology  firms  and  estab-
lished,  large,  and  international  (bio)pharmaceutical 
companies  have  a  significant  impact  on  the  survival 
and growth of these new biotechnology firms. 
Our  evidence  supports  the  assertion  by  Fisken  and 
Rutherford  (2002;  tinyurl.com/c2xoaxv):  “while  a  small 
number of companies with access to a large supply of 
capital  may  be  able  to  complete  downstream  integra-
tion and revert to the [fully integrated pharmaceutical 
company]  model,  the  majority  of  biotechnology  com-
Box 1. The case of ThromboGenics
ThromboGenics (thrombogenics.com) is a biopharma-
ceutical company focused on the discovery and de-
velopment  of  innovative  medicines  for  the 
treatment of eye diseases. The company was estab-
lished in the 1980s as a spin-off of the University of 
Leuven. ThromboGenics developed over the years 
from a university spin-off to a fully integrated spe-
cialty pharmaceutical company. It is now the “star” 
amongst new biotechnology firms in Belgium. 
ThromboGenics'  lead  product,  Jetrea  (ocriplas-
min), has been approved by the FDA and the EMA, 
and  the  company  recently  signed  an  important 
strategic partnership with Alcon (Novartis) to com-
mercialize  Jetrea  outside  the  United  States 
(tinyurl.com/c6795v9).Technology Innovation Management Review April 2013
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Table 1. Sample of Belgian biotechnology firms and their strategic partnership alliances Technology Innovation Management Review April 2013
28 www.timreview.ca
About the Author
Jean-Pierre Segers is Dean of the Business School at 
PXL  University  College  in  Hasselt,  Belgium  (pxl.be), 
and he is the Chairman and co-founder of Creative 
Inc. (creativeinc.be). He holds a Master's degree in Ap-
plied Economics and Public Affairs and is a former 
researcher in the Small Business Research Institute 
at the University of Brussels. His main research in-
terests  are  small  businesses  and  entrepreneurship; 
innovation  and  technology  management;  national 
and  regional  systems  of  innovation;  and  public-
private partnerships.
Citation: Segers, J-P. 2013. Strategic Partnerships and 
Open Innovation in the Biotechnology Industry in 
Belgium. Technology Innovation Management Review. 
April 2013: 23-28. 
Keywords: strategic partnerships, biotechnology, Belgium, 
open innovation, business models, R&D
Strategic Partnerships and Open Innovation in the Biotechnology Industry in Belgium
Jean-Pierre Segers
panies  will  instead  need  to  further  develop  sophistic-
ated relationship management skills in order to extract 
greater value from relationships with customers, collab-
orators and strategic partners”. Our conclusion is that 
the future of new biotechnology firms in Belgium lies in 
the effective establishment of strategic partnering alli-
ances. In future studies, the impacts of open innovation 
and novel business models warrant further attention.